Why glucose avoids orocecal transit pitfalls

FeatureGlucose Breath TestLactulose Breath TestAbsorption siteProximal small intestine (duodenum/proximal jejunum) 1Non-absorbable; reaches cecum intactDependence on orocecal transitMinimal—absorbed before reaching colonHigh—requires transit to cecum for fermentationFalse-positive mechanismColonic fermentation of unabsorbed glucose (rare, ≈5% reaches colon) 2Rapid transit delivers lactulose to cecum before 90-minute cutoff 3Primary utilityDetects proximal SIBOMeasures orocecal transit time more than SIBO 4

The North American Consensus explicitly states that breath testing is useful for SIBO diagnosis but not for assessment of oro-cecal transit 1, recognizing that lactulose-based tests primarily reflect transit variation rather than bacterial overgrowth in the small intestine 3 5.

Specific considerations for this patient with rapid gastric emptying

In this case with accelerated gastric emptying (92.7% at 2 hours), glucose actually has enhanced diagnostic utility:

1. Rapid gastric delivery ensures prompt presentation of substrate to the proximal small bowel, where SIBO would be detected
2. Minimal colonic contamination risk because glucose is absorbed proximally; even with rapid transit, only a small fraction reaches the cecum
3. Contrast with lactulose: In patients with rapid transit, lactulose would produce false-positive results by reaching the cecum before the 90-minute diagnostic window 3 4

Limitations to acknowledge

Despite these advantages, GBT is not without methodological concerns:

• False negatives: Glucose may miss distal ileal SIBO because absorption occurs before the substrate reaches more distal bacterial populations 6
• False positives from colonic fermentation: Scintigraphy studies demonstrate that 48% of abnormal glucose breath tests may represent colonic fermentation rather than true SIBO, particularly in patients with prior upper gastrointestinal surgery 2
• Rapid transit confounding: While less problematic than with lactulose, very rapid orocecal transit could theoretically deliver unabsorbed glucose to the cecum sooner than expected

The 2024 ESNM/ANMS clinical practice update notes that glucose breath testing has "better performance when pre-test probability is high" but acknowledges a "substantial false-positive rate in DGBI" 4. For this patient with cyclic vomiting syndrome and food intolerances, the clinical pre-test probability for SIBO remains reasonable given the dysmotility context, making GBT interpretation valid though requiring correlation with clinical response.

If you'd like, next I can:

Sources:

1. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. The American Journal of Gastroenterology, 2017
2. Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth. Clinical Gastroenterology and Hepatology, 2016
3. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut, 2011
4. Critical appraisal of the SIBO hypothesis and breath testing: a clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American Neurogastroenterology and Motility Society (ANMS). Neurogastroenterology and Motility, 2024
5. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut, 2013
6. Endoscopic-assisted glucose breath test (EAGBT) for evaluating distal small intestinal bacterial overgrowth (SIBO): correlation of nuclear imaging with breath testing. Neurogastroenterology and Motility, 2026

Mast cell activation syndrome
Recurrent, episodic systemic symptoms caused by mast-cell mediator release, often resembling anaphylaxis.

Consensus diagnosis requires all three:

• Recurrent acute symptoms involving at least 2 organ systems simultaneously (e.g., flushing/urticaria/angioedema; crampy abdominal pain, vomiting, or diarrhea; wheezing/dyspnea; hypotension, presyncope/syncope, or tachycardia).

• Objective event-related mediator elevation, preferably acute serum tryptase obtained within 1–4 hours of onset, exceeding:

  $$\text{baseline tryptase} \times 1.2 + 2\ \text{ng/mL}$$

  Urinary N-methylhistamine, leukotriene E4, and 2,3-dinor-11β-prostaglandin F2α may be adjunctive tests.

• Meaningful response to mast-cell mediator-directed therapy.

Classification

• Primary/clonal MCAS: KIT-mutated or other clonal mast-cell disease; evaluate for systemic mastocytosis.
• Secondary MCAS: driven by an identifiable process, commonly IgE-mediated allergy.
• Idiopathic MCAS: no clonal disease or external trigger identified after an appropriate evaluation.

Initial practical evaluation

• Document episode phenotype, timing, reproducible triggers, and multisystem involvement.
• Obtain baseline tryptase when asymptomatic and acute tryptase during a representative flare.
• Consider 24-hour or spot urine mediator testing collected during symptoms per the performing laboratory’s protocol.
• Evaluate for IgE-mediated allergy, medication reactions, hereditary alpha-tryptasemia, and clonal mast-cell disease when indicated.
• Maintain a broad differential for episodic flushing, diarrhea, tachycardia, hypotension, and abdominal symptoms.

Symptom-directed treatment framework

• Trigger identification and avoidance.
• H1 blocker: cetirizine (Zyrtec), fexofenadine (Allegra), or loratadine (Claritin).
• H2 blocker for GI symptoms: famotidine (Pepcid).
• Oral cromolyn sodium (Gastrocrom) for bloating, diarrhea, and cramping.
• Leukotriene modifier: montelukast (Singulair) or zileuton (Zyflo).
• Selected refractory cases: ketotifen (Zaditor), omalizumab (Xolair), or aspirin (Bayer) when clinically appropriate and tolerated.
• Epinephrine autoinjector (EpiPen) for prior systemic anaphylaxis or airway angioedema.

MCAS should not be diagnosed solely on chronic nonspecific symptoms, isolated baseline mediator elevation, food intolerance, or response to antihistamines; the episodic multisystem phenotype plus objective mediator evidence is central to diagnostic specificity. 1

Sources:

1. AAAAI mast cell disorders committee work group report: mast cell activation syndrome (MCAS) diagnosis and management. The Journal of Allergy and Clinical Immunology, 2019

stercoral ulcer—a pressure-induced ischemic mucosal injury from fecal stasis and impaction. The histology can show acute colitis sometimes with neutrophils in the lamina propria and surface epithelium, reactive changes, and preserved architecture which supports an ischemic/pressure mechanism.

Treatment is aggressive constipation management. 

Sources:

1. Solitary rectal ulcer syndrome and stercoral ulcers. Gastroenterology Clinics of North America, 2009
2. Stercoral colitis complicated with ischemic colitis: a double-edge sword. BMC Gastroenterology, 2017

26,000 - 50,000 CFU/mL Streptococcus viridans group Abnormal 4,000 CFU/mL Lactobacillus species Abnormal 5,000 CFU/mL Gram Positive Cocci Abnormal 5,000 CFU/mL Probable Neisseria species Abnormal 4,000 CFU/mL Probable Haemophilus species Abnormal 9,000 CFU/mL Anaerobic Gram Negative Rods Abnormal